← Back to Search

Illuccix Total Body PET-CT for Prostate Cancer

Q: Are there any openings in this trial for participants at the present time?

<p>Per the information hosted on clinicaltrials.gov, it appears that this particular trial is not currently recruiting participants, despite having been posted initially on October 1st 2022 and edited most recently on September 26th 2022. Although recruitment has ceased for this study, there are still 1258 other trials actively seeking patients at present.</p>

Phase < 1

Recruiting

Research Sponsored by BAMF Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

Study Summary

This trial will use Illuccix to establish a standard scanning protocol for PET-CT imaging on the United Imaging scanner uEXPLORER.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparing the imaging quality using low dose and high dose Ga-68 PSMA-11 at various scan lengths.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Low DoseExperimental Treatment1 Intervention

3 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.

Group II: High doseExperimental Treatment1 Intervention

7 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Telix Pharmaceuticals (Innovations) Pty LimitedIndustry Sponsor

17 Previous Clinical Trials

1,255 Total Patients Enrolled

2 Trials studying Prostate Cancer

160 Patients Enrolled for Prostate Cancer

BAMF HealthLead Sponsor

1 Previous Clinical Trials

30 Total Patients Enrolled

Telix International Pty LtdIndustry Sponsor

18 Previous Clinical Trials

1,267 Total Patients Enrolled

2 Trials studying Prostate Cancer

160 Patients Enrolled for Prostate Cancer

Media Library

Low Dose Clinical Trial Eligibility Overview. Trial Name: NCT05558956 — Phase < 1

Prostate Cancer Research Study Groups: Low Dose, High dose

Prostate Cancer Clinical Trial 2023: Low Dose Highlights & Side Effects. Trial Name: NCT05558956 — Phase < 1

Low Dose 2023 Treatment Timeline for Medical Study. Trial Name: NCT05558956 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings in this trial for participants at the present time?

"Per the information hosted on clinicaltrials.gov, it appears that this particular trial is not currently recruiting participants, despite having been posted initially on October 1st 2022 and edited most recently on September 26th 2022. Although recruitment has ceased for this study, there are still 1258 other trials actively seeking patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

2022. "Total Body PET-CT Imaging of Prostate Cancer Using Illuccix". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05558956.